Apyx Medical Corporation (NASDAQ:APYX) Q2 2023 Earnings Call Transcript

Frank Takkinen: Okay. That make sense. Thanks for taking the questions.

Charles Goodwin: Thank you.

Operator: Thank you. Our next question is from Matt Hewitt with Craig-Hallum. Please proceed with your question.

Matthew Hewitt: Just a follow-up regarding the OUS opportunity. I realize you have a lot on your plate at the moment. But are you still seeking other incremental OUS approvals? I believe there’s been a few countries in the past that you talked about potentially going after. I’m just curious if those are still in the works. Thanks.

Charles Goodwin: Yeah, for sure. We did not obtain any new registrations in Q2 and our guidance doesn’t assume any contributions for many new countries. But as you mentioned, the two big markets that we are not in are South Korea and China. And so we are still pursuing both of those markets. And we look forward to the day that I can tell you that we got clearance in both of those places. So we’ll make sure that everybody knows when that happens for sure.

Matthew Hewitt: Sounds good. Thank you.

Charles Goodwin: Thank you.

Operator: Thank you. We are currently showing no remaining questions at this time. And with that, this does conclude our conference today. Thank you for your participation.